Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 1:56 PM
Ignite Modification Date: 2025-12-24 @ 1:56 PM
NCT ID: NCT00249795
Eligibility Criteria: Inclusion Criteria: Should fulfill the eligibility criteria for ACTIVE A or ACTIVE W trial and: * have a systolic blood pressure of at least 110 mmHg * not already receiving an angiotensin receptor blocking agent, unless they are willing and able to be changed to another antihypertensive agent * no previous intolerance to angiotensin receptor blocking agents * no proven indication for angiotensin receptor blocking agents, unless an Angiotensin Converting Enzyme (ACE) inhibitor can be substituted Exclusion Criteria: Patients will be excluded from ACTIVE study if any of the following are present: * requirement for clopidogrel (such as recent coronary stent procedure) * requirement for oral anticoagulant (such as prosthetic mechanical heart valve) * prior intolerance to acetylsalicyclic acid (ASA) or clopidogrel * documented peptic ulcer disease within the previous 6 months * prior intracerebral hemorrhage * significant thrombocytopenia (platelet count \<50 x 10(9)/L) * psychosocial reason making study participation impractical * geographic reason making study participation impractical * ongoing alcohol abuse * mitral stenosis * pregnant or nursing woman or woman of child bearing potential and not on effective birth control for at least one month prior to start of study or not willing to continue on birth control for duration of study * severe comorbid condition such that the patient is not expected to survive 6 months * patient currently receiving an investigational pharmacologic agent * requirement for chronic (\> 3 months) non-cyclooxygenase-2 (non-COX-2) inhibitor nonsteroidal anti-inflammatory drug (NSAID) therapy unless willing enrolled in ACTIVE A
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Study: NCT00249795
Study Brief:
Protocol Section: NCT00249795